FDA Approval Sought for Belantamab Mafodotin in Relapsed/Refractory Myeloma

A biologics license application has been filed with the FDA for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Read the full article here

Related Articles